Whalesbook
Biocon Pursues In-Licensing to Speed Up Biosimilar Growth
Biocon is actively seeking in-licensing deals to quickly expand its range of biosimilar drugs. This strategy aims to use its global sales network to bring products to market faster, avoiding the long development times and high costs of creating them internally. CEO Shreehas Tambe said Biocon is open to acquiring external products that fit its current capabilities, shifting towards a mix of internal and external growth. This move follows major investments in its R&D and scale, especially after fully integrating Viatris' global biosimilars business in December 2023. Biocon's large commercial presence in the US, Europe, Japan, and over 70 other markets can now be used to sell and distribute products from other companies. This complements its existing 12 biosimilars, which are used by millions of patients each year. The biosimilars business is a key driver, bringing in Rs 10,431 crore in revenue for FY26, a 16% rise from the previous year, with EBITDA margins around 26%. Management expects these margins to reach 30% soon. By focusing less on heavy investment and more on external assets, Biocon aims to improve how well it uses its facilities, its profit margins, and returns for investors.
The Competitive Biosimilar Landscape
The global biosimilars market is expected to grow steadily, with a projected compound annual growth rate of 13.3% through 2030, but it is also becoming very crowded. Companies like Sandoz, Pfizer, and Amgen already hold significant market share, pushing Biocon to find external products to stay competitive. Biocon ranks among the top 5 global biosimilar companies and top 3 in insulins, operating in over 120 countries. However, the US market, which generates over 60% of Biocon's biosimilar revenue along with Europe, has seen slower-than-expected adoption. Biosimilar market share in the US was around 2% in late 2023. This slow uptake, which some call a 'marathon' not a sprint, creates challenges. These are made worse by changing regulations and strong price competition as patents on original drugs expire. While Biocon has reached important goals, like launching its first interchangeable glargine in the US, continued growth needs a flexible strategy for its product lineup.
Valuation, Margin Concerns, and FDA Risks
Despite its efforts, Biocon faces significant challenges. Its valuation, with a P/E ratio around 160-167 as of May 2026, is high compared to the industry average of about 43. This suggests high expectations for future growth that might be hard to achieve. The company's debt-to-equity ratio is around 0.85 (or 50%), showing moderate debt that needs careful handling for new acquisitions. Profitability is also a worry. Reports suggest Biocon's current model isn't generating enough shareholder value, with a five-year average Return on Equity (ROE) of 5.62% and Return on Capital Employed (ROCE) of 4.36%, both well below industry averages. Its interest coverage is also tight at 2x EBIT. Integrating the Viatris business has been complex and expensive, adding to margin issues. Additionally, past FDA inspections at Biocon's manufacturing sites in Bangalore and Malaysia have raised concerns. These observations create a risk of regulatory delays or necessary improvements, which could affect launch schedules and costs. Fierce price competition in the US biosimilar market and possible patent lawsuits add more risks to future revenue and profit growth.
Future Outlook: Profitability and New Drug Markets
After a period of significant investment and building capabilities, Biocon is now prioritizing better use of its facilities, increasing profit margins, and improving returns on its investments. For FY26, the company reported a 13% revenue increase to Rs 16,927 crore. However, net profit dropped sharply by 74% year-on-year to Rs 368.8 crore. Management expects new biosimilar products launched recently to grow in FY27, with a focus on steady, profitable expansion. This shift from a 'Preserve' phase to a 'Consolidation' phase for FY27 is intended to set up the business for long-term success by concentrating on operational efficiency and higher profits. Biocon is also looking ahead by expanding into GLP-1s and peptides, recognizing the future potential in drugs for diabetes and obesity.